CannPal CPAT-01 Results Presentation and Research Abstract

KEY TAKEAWAYS:

• CannPal presented at the 2019 AVA (Australian Veterinary Association) Innovation, Research and Development Symposium on Sunday, the 5th of May
• Dr Margaret Curtis Presented on the Company’s Phase 1 research results for CPAT-01, in development for pain and inflammation control in dogs
• Attached is a copy of the research abstract to be published in the AVJ (Australian Veterinary Journal), Australia’s premier veterinary scientific journal
• The Company has strengthened its IP for CPAT-01 with the filing of a further provisional patent application incorporating the results of CannPal’s ongoing research.

Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to enclose a copy of the presentation that was delivered by Dr Margaret Curtis at the 2019 AVA (Australian Veterinary Association) Innovation, Research and Development Symposium on Sunday the 5th of May.

Also enclosed is a copy of the research abstract that will be published in the AVJ (Australian Veterinary Journal). The AVJ is Australia’s premier veterinary scientific journal, reaching an audience of over 5000 AVA members.

Dr Margaret Curtis presented on the pharmacokinetic, safety, gene expression and inflammatory biomarker results from the Company’s robust randomised three group parallel pharmacokinetic study that was completed in 2018 for CPAT-01, the Company’s lead drug candidate in development for pain and inflammation control in dogs.

Strengthening IP

The Company would also like to confirm it has filed a further provisional patent application relating to the CPAT-01 program incorporating the results of CannPal’s ongoing research.

This further provisional application builds on an earlier filed provisional patent application for the CPAT-01 formulation [ASX Announcement: June 18, 2018].

The invention relates to a composition comprising a combination of Δ9- tetrahydrocannabinol (THC) and cannabidiol (CBD). The invention also relates to methods using the composition.

CannPal’s Head of Research and Development, Dr Margaret Curtis:

“The Innovation Symposium was a fantastic opportunity to showcase the breadth and depth of CannPal’s research to the veterinary fraternity in Australia. It was a pleasure to share some of the exciting data that CannPal is generating with the wider scientific community, which we believe can help contribute to the advancement of cannabinoid- derived therapeutic research across all species.”

About CannPal Animal Therapeutics

CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.
CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovate therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.